Your browser is no longer supported. Please, upgrade your browser.
DMPI DelMar Pharmaceuticals, Inc. daily Stock Chart
DelMar Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.41 Insider Own0.10% Shs Outstand11.42M Perf Week11.15%
Market Cap11.80M Forward P/E- EPS next Y-0.42 Insider Trans0.00% Shs Float11.26M Perf Month42.13%
Income-7.90M PEG- EPS next Q-0.13 Inst Own2.00% Short Float1.41% Perf Quarter62.58%
Sales- P/S- EPS this Y41.80% Inst Trans3.73% Short Ratio0.17 Perf Half Y97.32%
Book/sh-0.09 P/B- EPS next Y36.40% ROA-131.50% Target Price- Perf Year-34.16%
Cash/sh0.45 P/C2.36 EPS next 5Y- ROE- 52W Range0.38 - 2.45 Perf YTD53.69%
Dividend- P/FCF- EPS past 5Y-22.90% ROI- 52W High-56.73% Beta1.92
Dividend %- Quick Ratio3.70 Sales past 5Y- Gross Margin- 52W Low178.95% ATR0.12
Employees4 Current Ratio3.70 Sales Q/Q- Oper. Margin- RSI (14)55.14 Volatility9.23% 14.14%
OptionableNo Debt/Eq- EPS Q/Q74.40% Profit Margin- Rel Volume0.27 Prev Close1.03
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume935.62K Price1.06
Recom2.00 SMA209.82% SMA5014.83% SMA20057.19% Volume260,263 Change2.91%
Aug-14-17Downgrade Maxim Group Buy → Hold
Jul-17-20 08:00AM  
Jun-24-20 08:30AM  
Jun-22-20 08:30AM  
Jun-10-20 08:30AM  
Jun-04-20 08:00AM  
Jun-01-20 08:00AM  
May-13-20 08:00AM  
May-10-20 10:29AM  
May-05-20 08:00AM  
Mar-26-20 08:00AM  
Mar-04-20 08:30AM  
Feb-19-20 08:00AM  
Feb-13-20 08:00AM  
Feb-10-20 09:21AM  
Feb-05-20 08:00AM  
Jan-29-20 08:00AM  
Dec-03-19 08:30AM  
Nov-25-19 12:17PM  
Nov-17-19 08:42AM  
Nov-14-19 08:00AM  
Nov-11-19 09:52AM  
Nov-05-19 08:30AM  
Oct-29-19 08:30AM  
Oct-24-19 08:30AM  
Oct-15-19 08:00AM  
Oct-10-19 08:30AM  
Sep-11-19 08:00AM  
Sep-10-19 08:00AM  
Sep-09-19 08:00AM  
Sep-04-19 08:30AM  
Aug-28-19 07:31AM  
Aug-27-19 11:42AM  
Aug-26-19 11:49AM  
Aug-16-19 07:33AM  
Aug-14-19 09:10AM  
Aug-13-19 09:00AM  
Jul-31-19 08:00AM  
Jul-24-19 12:17PM  
Jul-10-19 05:30AM  
Jun-27-19 07:26AM  
Jun-25-19 05:28PM  
Jun-11-19 05:30AM  
Jun-05-19 03:10PM  
Jun-03-19 08:45AM  
May-29-19 09:00AM  
May-23-19 02:30PM  
May-20-19 05:30AM  
May-15-19 05:30AM  
May-08-19 08:12AM  
May-07-19 04:53PM  
Apr-04-19 05:30AM  
Apr-03-19 05:30AM  
Feb-20-19 05:30AM  
Feb-19-19 02:30PM  
Feb-12-19 05:30AM  
Feb-07-19 05:30AM  
Nov-23-18 07:30AM  
Nov-20-18 05:30AM  
Nov-14-18 05:30AM  
Oct-26-18 11:25AM  
Oct-16-18 10:06AM  
Oct-10-18 05:30AM  
Sep-24-18 06:00AM  
Sep-19-18 05:23PM  
Jun-26-18 06:00AM  
Jun-25-18 06:00AM  
May-30-18 07:50AM  
May-22-18 05:30AM  
May-17-18 05:30AM  
Apr-17-18 02:00PM  
Apr-16-18 09:00AM  
Feb-28-18 08:20AM  
Feb-20-18 12:00PM  
Feb-14-18 05:39PM  
Dec-26-17 07:33AM  
Dec-08-17 01:33PM  
Nov-30-17 06:25PM  
Nov-21-17 03:06PM  
Nov-14-17 10:00AM  
Nov-13-17 06:14PM  
Nov-07-17 04:05PM  
Oct-31-17 05:30AM  
Oct-24-17 12:17PM  
Oct-17-17 02:11PM  
Oct-10-17 09:30AM  
Oct-05-17 07:50AM  
Oct-04-17 11:00AM  
Oct-03-17 05:30AM  
Sep-28-17 06:50PM  
Sep-27-17 05:30AM  
Sep-26-17 10:00AM  
Sep-22-17 02:20PM  
Sep-21-17 08:00AM  
Sep-20-17 03:31PM  
DelMar Pharmaceuticals, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. Its product candidate is VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China; and Duke University to evaluate VAL-083 as a front-line treatment for newly diagnosed patients with GBM. DelMar Pharmaceuticals, Inc. was founded in 2009 and is headquartered in San Diego, California.